Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Update

Hoth Therapeutics, Inc. (NASDAQ:HOTH) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 783,318 shares, an increase of 143.8% from the January 15th total of 321,350 shares. Approximately 5.4% of the shares of the stock are short sold. Based on an average daily volume of 903,297 shares, the days-to-cover ratio is presently 0.9 days. Based on an average daily volume of 903,297 shares, the days-to-cover ratio is presently 0.9 days. Approximately 5.4% of the shares of the stock are short sold.

Hoth Therapeutics Stock Up 5.2%

Shares of HOTH stock traded up $0.05 during mid-day trading on Thursday, reaching $0.98. 895,742 shares of the stock traded hands, compared to its average volume of 706,025. The stock’s fifty day simple moving average is $1.03 and its two-hundred day simple moving average is $1.27. Hoth Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.12. The company has a market cap of $15.20 million, a price-to-earnings ratio of -0.92 and a beta of 0.56.

Hoth Therapeutics (NASDAQ:HOTH) last posted its earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.20). On average, equities research analysts anticipate that Hoth Therapeutics will post -1.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Hoth Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in Hoth Therapeutics in the third quarter valued at approximately $232,000. Virtu Financial LLC acquired a new stake in shares of Hoth Therapeutics during the third quarter worth $184,000. Kestra Private Wealth Services LLC bought a new position in Hoth Therapeutics during the third quarter worth $51,000. Geode Capital Management LLC lifted its holdings in Hoth Therapeutics by 18.0% in the fourth quarter. Geode Capital Management LLC now owns 181,112 shares of the company’s stock valued at $179,000 after buying an additional 27,577 shares during the period. Finally, Lido Advisors LLC acquired a new position in Hoth Therapeutics in the third quarter valued at $32,000. Institutional investors and hedge funds own 7.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on HOTH. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a report on Thursday, December 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Hoth Therapeutics in a research note on Monday, December 22nd. Finally, Wall Street Zen downgraded Hoth Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $5.00.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.